Folate receptor-a (FOLR1) expression and function in triple negative tumors

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Necela, Brian M ^a   Crazier, Jennifer A ^a   Andorfer, Cathy A ^a   Lewis Tuffin, Laura ^a   Kachergus, Jennifer M ^a   Geiger, Xochiquetzal J ^a   Kalari, Krishna R ^b   Serie, Daniel J ^a   Sun, Zhifu ^b   Aspita, Alvaro Moreno ^a   O'Shannessy, Daniel J ^c   Maltzman, Julia D ^c   McCullough, Ann E ^d   Pockaj, Barbara A ^d   Cunliffe, Heather E ^e   Ballman, Karla V ^b   Thompson, E Aubrey ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Department of Pathology Laboratory Medicine Mayo Clinic ^*  (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOLATE RECEPTOR 1; MESSENGER RNA; FOLR1 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; SHORT HAIRPIN RNA;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; BREAST CANCER CELL LINE; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLATE UPTAKE; GENE SILENCING; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; PROTEIN DEPLETION; PROTEIN LOCALIZATION; RNA SEQUENCE; TRANSPORT AT THE CELLULAR LEVEL;

CELL LINE, TUMOR; FEMALE; FOLATE RECEPTOR 1; HUMANS; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84929459286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/joumal.pone.0122209     Document Type: Article

References (37)

1. De Santis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62. doi: 10.3322/caac.21203 PMID: 24114568
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47. doi: 10.1093/annonc/mdr304 PMID: 21709140
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. PMID: 16236738
4. Palmieri FM, Myatt CV, Perez EA. Adjuvant trastuzumab for HER2-positive early breast cancer. Clin J Oncol Nurs. 2010;14(3):326-36. doi: 10.1188/10. CJON.326-336 PMID: 20529794
5. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16-32.
6. Fomier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012;18(1):41-51. doi: 10.1111/j.1524-4741.2011.01175.x PMID: 22098334
7. Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol. 2011;23(6):566-77. doi: 10.1097/CCO.0b013e32834bf8ae PMID: 21986848
8. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010 PMID: 22454417
9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. doi: 10.1172/JCI45014 PMID: 21633166
10. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, et al. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene. 2000;19(41):4754-63. PMID: 11032026
11. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243-50. PMID: 16453285
12. Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, et al. Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201. doi: 10.1371/joumal.pone.0047201 PMID: 23144806
13. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992;52(23):6708-11. PMID: 1330299
14. Toffoli G, Cemigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. IntJCancer. 1997;74(2):193-8. PMID: 9133455
15. Parker N, Turk M J, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005:338(2):284-93. PMID: 15745749
16. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994:73(9):2432-43. PMID: 7513252
17. Evans CO, Reddy P, Brat DJ, O'Neill EB, Craige B, Stevens VL, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res. 2003;63(14):4218-24. PMID: 12874029
18. Clinical Trials website. Available: http://www.clinicaltrails.gov. Accessed 24 February 2015.
19. Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, et al. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther. 2013;14(11):1032-8. doi: 10. 4161/cbt.26106 PMID: 24025360
20. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC 145. Int J Cancer. 2007;121(7):1585-92. PMID: 17551919
21. Maurer AH, Elsinga P, Fanti S, Nguyen B, Oyen WJ, Weber WA. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med. 2014;55(5):701-4. doi: 10.2967/jnumed.113.133074 PMID: 24732155
22. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256-62. doi: 10.1016/i.cbpa.2009.03.022 PMID: 19419901
23. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938-42. PMID: 17487842
24. Zhang Z, Wang J, Tacha DE, Li P, Bremer RE, Chen H, et al. Folate Receptor alpha Associated With Triple-Negative Breast Cancer and Poor Prognosis. Arch Pathol Lab Med. 2014;138(7):890-5. doi: 10. 5858/arpa.2013-0309-OA PMID: 24028341
25. O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2012;1:22. doi: 10.1186/2193-1801-1-22 PMID: 23961352
26. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, et al. Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget. 2011;2(12):1227-43. PMID: 22204844
27. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011;39(15).
28. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One. 2011;6(2).
29. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25. doi: 10.1186/qb-2009-10-3-r25 PMID: 19261174
30. Trapnell C, Pachter L, Salzberg SL. Top Hat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-11. doi: 10.1093/bioinformatics/btp120 PMID: 19289445
31. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9. doi: 10.1038/nature10933 PMID: 22495314
32. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841-2. doi: 10.1093/bioinformatics/btq033 PMID: 20110278
33. Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008;108(2):191-201. doi: 10.1007/s10549-007-9596-6 PMID: 18297396
34. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313(4):856-62. PMID: 14706621
35. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res. 2014;20(4):782-90. doi: 10.1158/1078-0432. CCR-13-0583 PMID: 24536073
36. Rochman H, Selhub J, Karrison T. Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 1985;8(1-2):71-5. PMID: 4064056
37. Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res. 2003;63(11):2820-8. PMID: 12782587